My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 266

    1.

    Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.

    Regensteiner JG, Bauer TA, Reusch JE.

    Diabetes Care. 2005 Dec;28(12):2877-83.PMID: 16306548 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.

    Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P.

    Diabetes Care. 2004 Feb;27(2):484-90.PMID: 14747233 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

    Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila P.

    Diabetes. 2002 Dec;51(12):3479-85.PMID: 12453903 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.

    Lautamäki R, Airaksinen KE, Seppänen M, Toikka J, Luotolahti M, Ball E, Borra R, Härkönen R, Iozzo P, Stewart M, Knuuti J, Nuutila P.

    Diabetes. 2005 Sep;54(9):2787-94.PMID: 16123370 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

    Osei K, Gaillard T, Schuster D.

    Metabolism. 2007 Jan;56(1):24-9.PMID: 17161222 [PubMed - indexed for MEDLINE]Related articles

    6.

    Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

    Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E.

    Diabetes Care. 2004 Jun;27(6):1349-57.PMID: 15161787 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.

    Juhl CB, Hollingdal M, Pørksen N, Prange A, Lönnqvist F, Schmitz O.

    J Clin Endocrinol Metab. 2003 Aug;88(8):3794-800.PMID: 12915671 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

    Sourij H, Zweiker R, Wascher TC.

    Diabetes Care. 2006 May;29(5):1039-45.PMID: 16644634 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Reduced skeletal muscle oxygen uptake and reduced beta-cell function: two early abnormalities in normal glucose-tolerant offspring of patients with type 2 diabetes.

    Thamer C, Stumvoll M, Niess A, Tschritter O, Haap M, Becker R, Shirkavand F, Bachmann O, Rett K, Volk A, Häring H, Fritsche A.

    Diabetes Care. 2003 Jul;26(7):2126-32.PMID: 12832324 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.

    Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P.

    Diabetes Care. 2003 Jul;26(7):2069-74.PMID: 12832315 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.

    Viljanen AP, Virtanen KA, Järvisalo MJ, Hällsten K, Parkkola R, Rönnemaa T, Lönnqvist F, Iozzo P, Ferrannini E, Nuutila P.

    J Clin Endocrinol Metab. 2005 Dec;90(12):6523-8. Epub 2005 Sep 27.PMID: 16189256 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus.

    Pagel-Langenickel I, Schwartz DR, Arena RA, Minerbi DC, Johnson DT, Waclawiw MA, Cannon RO 3rd, Balaban RS, Tripodi DJ, Sack MN.

    Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2659-66. Epub 2007 Sep 21.PMID: 17890427 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

    Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.

    J Clin Endocrinol Metab. 2008 Jan;93(1):118-24. Epub 2007 Oct 23.PMID: 17956948 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.

    Diabetes Care. 2006 Nov;29(11):2371-7.PMID: 17065670 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.

    Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M.

    Diabet Med. 2008 Mar;25(3):333-40.PMID: 18307460 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.

    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.

    Diabetologia. 2001 Dec;44(12):2210-9.PMID: 11793023 [PubMed - indexed for MEDLINE]Related articles

    19.

    The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function.

    Schrauwen-Hinderling VB, Mensink M, Hesselink MK, Sels JP, Kooi ME, Schrauwen P.

    J Clin Endocrinol Metab. 2008 Jul;93(7):2917-21. Epub 2008 May 6.PMID: 18460571 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.

    Hwang YC, Lee EY, Lee WJ, Cha BS, Yoon KH, Park KS, Lee MK.

    Metabolism. 2008 Apr;57(4):479-87.PMID: 18328348 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity